None
Quote | AN2 Therapeutics Inc. (NYSE:ANTX)
Last: | $ |
---|---|
Change Percent: | -1.27% |
Open: | $57.76 |
Close: | $56.86 |
High: | $58.14 |
Low: | $56.86 |
Volume: | 315,708 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | AN2 Therapeutics Inc. (NYSE:ANTX)
2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...
2024-03-29 06:57:13 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics reports FY results AN2 Therapeutics extends losses as Leerink cuts on trial setback Seeking Alpha’s Quant Rating on A...
Message Board Posts | AN2 Therapeutics Inc. (NYSE:ANTX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ANTX News Article - AN2 Therapeutics to Present at Upcoming Investor Conferences | whytestocks | investorshangout | 11/02/2022 8:20:48 PM |
whytestocks: $ANTX News Article - NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million | whytestocks | investorshangout | 09/29/2022 2:05:48 PM |
whytestocks: $ANTX News Article - AN2 Therapeutics Reports Second Quarter 2022 Financial Results and | whytestocks | investorshangout | 08/11/2022 8:40:52 PM |
whytestocks: $ANTX News Article - AN2 Therapeutics Reports First Quarter 2022 Financial Results and | whytestocks | investorshangout | 05/10/2022 8:35:52 PM |
whytestocks: $ANTX News Article - AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Direc | whytestocks | investorshangout | 05/09/2022 12:30:49 PM |
News, Short Squeeze, Breakout and More Instantly...
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
NYSE Market:
2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and inve...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...